X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (134) 134
humans (118) 118
index medicus (107) 107
female (80) 80
male (75) 75
middle aged (75) 75
aged (64) 64
lung neoplasms - drug therapy (61) 61
chemotherapy (57) 57
carcinoma, non-small-cell lung - drug therapy (54) 54
adult (52) 52
lung cancer (50) 50
lung neoplasms - pathology (42) 42
respiratory system (39) 39
cancer (38) 38
aged, 80 and over (37) 37
lung cancer, non-small cell (35) 35
treatment outcome (34) 34
antineoplastic combined chemotherapy protocols - therapeutic use (32) 32
article (32) 32
carcinoma, non-small-cell lung - pathology (29) 29
neoplasm staging (27) 27
antineoplastic agents - therapeutic use (26) 26
care and treatment (26) 26
erlotinib (26) 26
hematology, oncology and palliative medicine (26) 26
lung neoplasms - genetics (26) 26
carcinoma, non-small-cell lung - genetics (24) 24
lung neoplasms - mortality (22) 22
therapy (22) 22
gefitinib (21) 21
nsclc (21) 21
open-label (21) 21
protein kinase inhibitors - therapeutic use (21) 21
docetaxel (20) 20
mutation (20) 20
research (19) 19
crizotinib (18) 18
metastasis (18) 18
clinical trials (17) 17
non-small cell lung cancer (17) 17
survival (17) 17
tumors (17) 17
patients (16) 16
carcinoma, non-small-cell lung - mortality (15) 15
non-small cell lung carcinoma (15) 15
receptor, epidermal growth factor - antagonists & inhibitors (15) 15
survival analysis (15) 15
survival rate (15) 15
carcinoma (14) 14
dose-response relationship, drug (14) 14
lung neoplasms - therapy (14) 14
cancer therapies (13) 13
cell lung-cancer (13) 13
disease-free survival (13) 13
expression (13) 13
prognosis (13) 13
pulmonary/respiratory (13) 13
safety (13) 13
acquired-resistance (12) 12
alectinib (12) 12
analysis (12) 12
carboplatin (12) 12
maximum tolerated dose (12) 12
abridged index medicus (11) 11
adenocarcinoma (11) 11
antineoplastic agents (11) 11
antineoplastic agents - adverse effects (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (11) 11
cisplatin (11) 11
drug therapy (11) 11
epidemiology (11) 11
follow-up studies (11) 11
medicine & public health (11) 11
multicenter (11) 11
non-small-cell lung cancer (11) 11
paclitaxel (11) 11
retrospective studies (11) 11
trial (11) 11
breast-cancer (10) 10
clinical trials as topic (10) 10
lung neoplasms - metabolism (10) 10
lymphomas (10) 10
receptor, epidermal growth factor - genetics (10) 10
taxoids - administration & dosage (10) 10
tyrosine kinase inhibitor (10) 10
antimitotic agents (9) 9
carcinoma, non-small-cell lung - metabolism (9) 9
ceritinib (9) 9
combined modality therapy (9) 9
disease progression (9) 9
drug resistance, neoplasm - genetics (9) 9
egfr (9) 9
immunotherapy (9) 9
incidence (9) 9
mutations (9) 9
pulmonary and respiratory medicine (9) 9
radiotherapy (9) 9
respiratory tract diseases (9) 9
tyrosine kinase inhibitors (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2016, 1st ed. 2016, Advances in experimental medicine and biology, ISBN 3319249320, Volume 890., x, 231
This, the second of two volumes on personalized medicine in lung cancer, touches upon the recent progress in targeted drug development based on genomics;... 
Lungs | Treatment | Cancer | Oncology | Cancer Research | Biomedicine
Book
Cancer Epidemiology Biomarkers & Prevention, ISSN 1055-9965, 02/2017, Volume 26, Issue 2 Supplement, pp. IA15 - IA15
Journal Article
Cancer, ISSN 0008-543X, 09/2015, Volume 121, Issue 18, pp. 3197 - 3200
Journal Article
Future Oncology, ISSN 1479-6694, 08/2018, Volume 14, Issue 18, pp. 1875 - 1882
Anaplastic lymphoma kinase (ALK) gene rearrangements as driver genetic alterations occur in approximately 2-4% of non-small-cell lung cancer (NSCLC) patients.... 
NSCLC | anaplastic lymphoma kinase | alectinib | ACQUIRED-RESISTANCE | OPEN-LABEL | PF-2341066 | ANTITUMOR-ACTIVITY | REARRANGEMENTS | CHEMOTHERAPY | ONCOLOGY | CERITINIB | C-MET | CRIZOTINIB | INHIBITOR
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10066, pp. 255 - 265
Journal Article
Current treatment options in oncology, 09/2018, Volume 19, Issue 11, p. 53
Approximately 15% of the over 220,000 new lung cancers diagnosed each year in the USA are small cell lung cancer (SCLC). The standard of care for SCLC patients... 
Journal Article
Advances in Experimental Medicine and Biology, ISSN 0065-2598, 10/2016, Volume 890, pp. 203 - 222
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1497 - 1508
Journal Article
2016, 1st ed. 2016., Advances in Experimental Medicine and Biology, ISBN 9783319249322, Volume 890
This, the second of two volumes on personalized medicine in lung cancer, touches upon the recent progress in targeted drug development based on genomics;... 
Medicine | Cancer research
Web Resource
Current Treatment Options in Oncology, ISSN 1527-2729, 06/2017, Volume 18, Issue 6, p. 1
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s11864-017-0479-8 
ALK | Brigatinib | Crizotinib | Alectinib | Lorlatinib | NSCLC | Sequence of therapy | Anaplastic lymphoma kinase | Ceritinib | Enzyme inhibitors | Development and progression | Lung cancer, Non-small cell | Drug therapy | Phosphotransferases | Health aspects | Testing
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 03/2012, Volume 13, Issue 2, pp. 96 - 106
Recent advances in understanding the importance of angiogenesis to tumor growth and distant metastasis has driven the development of antiangiogenic therapies... 
Nonsmall-cell lung cancer | Antiangiogenic agents | Tolerability | Safety | Bevacizumab
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 897 - 907
Journal Article
Current Treatment Options in Oncology, ISSN 1527-2729, 11/2018, Volume 19, Issue 11, pp. 1 - 10
Journal Article
Cancer, ISSN 0008-543X, 09/2015, Volume 121, Issue 18, pp. 3197 - 3200
In a randomized trial, the combination of the cyclooxygenase 2 (COX‐2) inhibitor celecoxib with erlotinib demonstrated improved progression‐free survival in... 
GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | ONCOLOGY | ANTICANCER AGENTS | TUMOR-METASTASIS | CELECOXIB | EXPRESSION | DOCETAXEL | ERLOTINIB | CHEMOTHERAPY | PROSTAGLANDIN-E2 | Lung Neoplasms - drug therapy | Female | Male | Carcinoma, Non-Small-Cell Lung - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.